Through our industry-leading network of more than 2,200 dialysis facilities, outpatient cardiac and vascular labs, and urgent care centers, as well as the country’s largest practice of hospitalist and post-acute providers, Fresenius Medical Care provides coordinated health care services at pivotal care points for hundreds of thousands of chronically ill customers throughout the continent.
As the world’s only vertically integrated renal company, we also offer specialty pharmacy and laboratory services, as well as manufacturing and distributing the most comprehensive line of dialysis equipment, disposable products and renal pharmaceuticals.
Our integrated approach helps to not only improve patients' health outcomes, but also reduce the total cost of care.
Around the world, we care for more than 290,000 renal patients in our global network of more than 3,400 dialysis clinics. At the same time, we operate more than 40 production sites on all continents, to provide dialysis products such as dialysis machines, dialyzers and related disposables.
Our strategy is geared toward sustainable growth. We aim to continuously improve the quality of life of patients with kidney disease by offering innovative products and treatment concepts of the highest quality.
Fresenius Medical Care’s corporate headquarters is in Bad Homburg, Germany. Our North American headquarters is in Waltham, Massachusetts and our Asian-Pacific headquarters is located in Hong Kong.
Fresenius Medical Care around the World
Fresenius Medical Care’s strength in numbers
- We offer dialysis services and products in more than 120 countries.
- Every 0.7 seconds we provide a dialysis treatment somewhere across the globe.
- We employ more than 110,000 people in more than 50 countries around the world, which includes approximately 60,000 in North America.
- In 2016, 50 percent of the dialysis machines sold worldwide were produced by Fresenius Medical Care.
- In 2016, Fresenius Medical Care generated revenues of more than $17.9 billion (USD).
- Fresenius Medical Care has been developing and producing dialysis products for more than four decades.
Research and development – focusing on four major trends
- Advances in medicine and technology
All the research in the world is meaningless unless it turns into meaningful results for patients, which is why our research and development efforts are designed to quickly turn new findings into market-ready products. This quick time to market enables us to offer safer and more effective individualized treatment to each and every patient. We focus on technologies to reduce product size and simplify their use, while integrating various treatment elements to create holistic therapy systems.
- Sustained growth in patient numbers
It is estimated that by 2020, there will be 3.8 million kidney patients worldwide, fueled by an increase in the number of people who suffer from diseases such as high blood pressure and diabetes. As the number of kidney patients rises, health care systems across the globe will be challenged to find the resources to care for them. Meeting the resulting demand for safe, effective and efficient therapies and associated technologies and products is central to our research and development activities.
- Increase in concomitant diseases
Our society is aging overall and the risk of developing end-stage renal disease increases with age. As patients age they also experience a greater likelihood of developing concomitant diseases such as cardiac and vascular conditions. Treating these patients’ comorbidities is increasingly a focal point of our research and development efforts.
- Rising cost pressure in health care
An aging population, growth in chronic illnesses, and the desire to offer new and improved technologies in patient care all present major long-term financial challenges to health care systems across the globe. For this reason, we believe successful product innovations must not be not only high quality, but also affordable. Based on our experience operating dialysis clinics, we consider these two priorities to be entirely compatible.